{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:23Z","timestamp":1790240603781,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":234,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100449","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:13:47Z","timestamp":1629850427000},"page":"100449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients"],"prefix":"10.1016","volume":"29","author":[{"given":"Remco","family":"de Kock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Knoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Baselmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben van den","family":"Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Brunsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkher","family":"Scharnhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Deiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100449_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00016-2019","article-title":"Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions","volume":"5","author":"Hummelink","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ctarc.2021.100449_bib0002","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00330-016-4357-8","article-title":"Complication rates of CT-guided transthoracic lung biopsy: meta-analysis","volume":"27","author":"Heerink","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ctarc.2021.100449_bib0003","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100449_bib0004","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1007\/s11033-020-05869-7","article-title":"Liquid biopsy approaches for pleural effusion in lung cancer patients","volume":"47","author":"Baburaj","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.ctarc.2021.100449_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2019.08.004","article-title":"Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients","volume":"136","author":"Song","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2021.100449_bib0006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2019.05.018","article-title":"Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung","volume":"135","author":"Wang","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2021.100449_bib0007","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/1759-7714.13201","article-title":"Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctarc.2021.100449_bib0008","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.3390\/cancers13112798","article-title":"Diving into the Pleural Fluid: liquid Biopsy for Metastatic Malignant Pleural Effusions","volume":"13","author":"Sorolla","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100449_bib0009","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","article-title":"Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer","volume":"7","author":"Morgensztern","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctarc.2021.100449_bib0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000338169","article-title":"Pleural effusion in lung cancer: more questions than answers","volume":"83","author":"Froudarakis","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.ctarc.2021.100449_bib0011","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1878-0261.12574","article-title":"Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions","volume":"13","author":"Villatoro","year":"2019","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctarc.2021.100449_bib0012","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jmoldx.2019.05.003","article-title":"Optimized (pre) analytical conditions and workflow for droplet digital PCR analysis of cell-free DNA from patients with suspected lung carcinoma","volume":"21","author":"de Kock","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctarc.2021.100449_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2021.01.003","article-title":"Therapy monitoring of EGFR positive non-small cell lung cancer patients using ddPCR multiplex assays monitoring NSCLC patients by ddPCR","author":"de Kock","year":"2021","journal-title":"J Molecular Diagnostics"},{"key":"10.1016\/j.ctarc.2021.100449_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctarc.2021.100449_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1759-7714.13006","article-title":"Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling","volume":"10","author":"Guo","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctarc.2021.100449_bib0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2021.100449_bib0017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/LCTT.S119644","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"LCTT."},{"key":"10.1016\/j.ctarc.2021.100449_bib0018","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100449_bib0019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/cyt.12517","article-title":"A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients","volume":"29","author":"Kawahara","year":"2018","journal-title":"Cytopathology"},{"key":"10.1016\/j.ctarc.2021.100449_bib0020","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1634\/theoncologist.2019-0147","article-title":"Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis","volume":"24","author":"Ryu","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100449_bib0021","article-title":"Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.ctarc.2022.100608","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:21:05Z","timestamp":1762842065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"alternative-id":["S2468294221001465"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100449","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100449"}}